Cargando…

Evaluation of Dimebon in cellular model of Huntington's disease

BACKGROUND: Dimebon is an antihistamine compound with a long history of clinical use in Russia. Recently, Dimebon has been proposed to be useful for treating neurodegenerative disorders. It has demonstrated efficacy in phase II Alzheimer's disease (AD) and Huntington's disease (HD) clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jun, Li, Qin, Bezprozvanny, Ilya
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577671/ https://www.ncbi.nlm.nih.gov/pubmed/18939977 http://dx.doi.org/10.1186/1750-1326-3-15

Ejemplares similares

Dimebon disappointment
por: Jones, Roy W
Publicado: (2010)

Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
por: Chen, Xi, et al.
Publicado: (2011)

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
por: Wang, Jun, et al.
Publicado: (2011)

Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo
por: Steele, John W, et al.
Publicado: (2009)

Tetrabenazine is neuroprotective in Huntington's disease mice
por: Wang, Hongyu, et al.
Publicado: (2010)

Ataxic Symptoms in Huntington’s Disease Transgenic Mouse Model Are Alleviated by Chlorzoxazone
por: Egorova, Polina A., et al.
Publicado: (2020)

Dimebon Slows Progression of Proteinopathy in γ-Synuclein Transgenic Mice
por: Bachurin, Sergey O., et al.
Publicado: (2011)

Differences in bioavailability and cognitive-enhancing activity exerted by different crystal polymorphs of latrepirdine (Dimebon(®))
por: Gorin, Boris I., et al.
Publicado: (2023)

A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice
por: Chaprov, Kirill, et al.
Publicado: (2021)

Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease
por: Eckert, Schamim H, et al.
Publicado: (2018)

Design, Synthesis, Molecular Docking Study and Biological Evaluation of Novel γ-Carboline Derivatives of Latrepirdine (Dimebon) as Potent Anticancer Agents
por: Voggu, Ramakrishna, et al.
Publicado: (2023)

Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice
por: Shelkovnikova, Tatyana A., et al.
Publicado: (2011)

Indirect inhibition of 26S proteasome activity in a cellular model of Huntington’s disease
por: Hipp, Mark S., et al.
Publicado: (2012)

Biological Aging and the Cellular Pathogenesis of Huntington’s Disease
por: Machiela, Emily, et al.
Publicado: (2020)

Correction of Huntington’s Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model
por: Pierzynowska, Karolina, et al.
Publicado: (2018)

Expression of genes encoding the calcium signalosome in cellular and transgenic models of Huntington's disease
por: Czeredys, Magdalena, et al.
Publicado: (2013)

Activation of Gq-Coupled Receptors in Astrocytes Restores Cognitive Function in Alzheimer’s Disease Mice Model
por: Gerasimov, Evgenii, et al.
Publicado: (2023)

STIM1 Protein Activates Store-Operated Calcium Channels in Cellular Model of Huntington’s Disease
por: Vigont, V. A., et al.
Publicado: (2014)

Monkey hybrid stem cells develop cellular features of Huntington's disease
por: Laowtammathron, Chuti, et al.
Publicado: (2010)

Structure-Based Modeling of Sigma 1 Receptor Interactions with Ligands and Cholesterol and Implications for Its Biological Function
por: Kim, Meewhi, et al.
Publicado: (2023)

“Dirty Dancing” of Calcium and Autophagy in Alzheimer’s Disease
por: Zhang, Hua, et al.
Publicado: (2023)

Conformational Models of APP Processing by Gamma Secretase Based on Analysis of Pathogenic Mutations
por: Kim, Meewhi, et al.
Publicado: (2021)

Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease
por: Popugaeva, Elena, et al.
Publicado: (2013)

ANN and Fuzzy Logic Based Model to Evaluate Huntington Disease Symptoms
por: Lauraitis, Andrius, et al.
Publicado: (2018)

Striatal network modeling in Huntington’s Disease
por: Ponzi, Adam, et al.
Publicado: (2020)

Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington disease
por: Eshraghi, Mehdi, et al.
Publicado: (2021)

Analysis of Non-Amyloidogenic Mutations in APP Supports Loss of Function Hypothesis of Alzheimer’s Disease
por: Kim, Meewhi, et al.
Publicado: (2023)

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition
por: Siebzehnrübl, Florian A., et al.
Publicado: (2018)

Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms
por: Pla, Patrick, et al.
Publicado: (2014)

Presenilins: A novel link between intracellular calcium signaling and lysosomal function?
por: Bezprozvanny, Ilya
Publicado: (2012)

A patient-derived cellular model for Huntington’s disease reveals phenotypes at clinically relevant CAG lengths
por: Hung, Claudia Lin-Kar, et al.
Publicado: (2018)

Differential Cellular Balance of Olfactory and Vomeronasal Epithelia in a Transgenic BACHD Rat Model of Huntington’s Disease
por: Krysewski, Lina-Marielle, et al.
Publicado: (2022)

Huntington Disease in Asia
por: Xu, Miao, et al.
Publicado: (2015)

Huntington’s Disease: Calcium Dyshomeostasis and Pathology Models
por: Kolobkova, Y.A., et al.
Publicado: (2017)

Humanistic Burden of Huntington Disease: Evidence From the Huntington Disease Burden of Illness Study
por: Rodriguez Santana, Idaira, et al.
Publicado: (2022)

AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease
por: Vázquez-Manrique, Rafael P., et al.
Publicado: (2016)

Striatal Pre-Enkephalin Overexpression Improves Huntington’s Disease Symptoms in the R6/2 Mouse Model of Huntington’s Disease
por: Bissonnette, Stéphanie, et al.
Publicado: (2013)

The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease
por: Liu, Jie, et al.
Publicado: (2014)

Metabolic State Determines Sensitivity to Cellular Stress in Huntington Disease: Normalization by Activation of PPARγ
por: Jin, Youngnam N., et al.
Publicado: (2012)

Therapeutic Effect of Berberine on Huntington’s Disease Transgenic Mouse Model
por: Jiang, Wenxiao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jeuoffg565j1tvj8mnubt69s93